We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CareDx (CDNA) Soars 11.2%: Is Further Upside Left in the Stock?
Read MoreHide Full Article
CareDx (CDNA - Free Report) shares ended the last trading session 11.2% higher at $24.91. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 5.2% loss over the past four weeks.
CareDx scored a strong price rise on investors’ optimism surrounding its impending fourth-quarter 2024 financial results, expected to release on Feb. 26 post the closing bell. The company’s preliminary results revealed an approximately 30% year-over-year growth in the fourth-quarter revenues. Testing services volume grew for the sixth consecutive quarter, rising 14% compared to the prior year. Adjusted EBITDA is expected to be a gain of between $25 million to $26 million.
This molecular diagnostics company is expected to post quarterly earnings of $0.07 per share in its upcoming report, which represents a year-over-year change of +141.2%. Revenues are expected to be $85.5 million, up 30.4% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For CareDx, the consensus EPS estimate for the quarter has been revised 13.2% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on CDNA going forward to see if this recent jump can turn into more strength down the road.
CareDx belongs to the Zacks Medical Services industry. Another stock from the same industry, LifeMD, Inc. (LFMD - Free Report) , closed the last trading session 5.5% higher at $6.89. Over the past month, LFMD has returned 37.8%.
LifeMD's consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.06. Compared to the company's year-ago EPS, this represents a change of +50%. LifeMD currently boasts a Zacks Rank of #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
CareDx (CDNA) Soars 11.2%: Is Further Upside Left in the Stock?
CareDx (CDNA - Free Report) shares ended the last trading session 11.2% higher at $24.91. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 5.2% loss over the past four weeks.
CareDx scored a strong price rise on investors’ optimism surrounding its impending fourth-quarter 2024 financial results, expected to release on Feb. 26 post the closing bell. The company’s preliminary results revealed an approximately 30% year-over-year growth in the fourth-quarter revenues. Testing services volume grew for the sixth consecutive quarter, rising 14% compared to the prior year. Adjusted EBITDA is expected to be a gain of between $25 million to $26 million.
This molecular diagnostics company is expected to post quarterly earnings of $0.07 per share in its upcoming report, which represents a year-over-year change of +141.2%. Revenues are expected to be $85.5 million, up 30.4% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For CareDx, the consensus EPS estimate for the quarter has been revised 13.2% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on CDNA going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
CareDx belongs to the Zacks Medical Services industry. Another stock from the same industry, LifeMD, Inc. (LFMD - Free Report) , closed the last trading session 5.5% higher at $6.89. Over the past month, LFMD has returned 37.8%.
LifeMD's consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.06. Compared to the company's year-ago EPS, this represents a change of +50%. LifeMD currently boasts a Zacks Rank of #3 (Hold).